No Data
No Data
HKEx Unusual Movement: Gilead Sciences Inc (01672) plummeted by 11%, with a significant pre-loss of more than 0.127 billion yuan in the first half of the year, and no sales revenue from the product, Remdesivir.
Geleshi Pharma-B (01672) fell by 11%. As of press time, it was down 11% to HKD 0.89 with a turnover of HKD 1.4689 million.
Ascletis Pharma Forecasts Wider Loss in H1; Shares Slide 6%
Galepharmaceutical -B(01672.HK) profit warning: expected significant increase in net loss for the first half of the year.
On August 7th, Grace Pharma-B(01672.HK) released an announcement that the Group is expected to incur a net loss attributable to equity holders of the company of RMB 127.3-132.3 million for the six months ended June 30, 2024, a significant increase from the net loss incurred in the same period of the previous year (about RMB 16.6 million). The Board of Directors believes that the increase in net loss attributable to equity holders is mainly due to the effective control of the COVID-19 epidemic in mainland China, which has led to a shrinking demand for ritonavir products in the market. Therefore, the company did not record any sales of ritonavir products in the first half of 2024.
Express News | Ascletis Pharma - Expected Result Due to Contraction of Market Demand for Ritonavir Product, Others
Express News | Ascletis Pharma Inc Sees Net Loss Attributable RMB127.3 Mln to RMB132.3 Mln for Six Months
ASCLETIS-B: PROFIT WARNING
No Data